# EvidenceDigest: Direct Oral Anticoagulants in Cancer-Associated Thrombosis
Clinical bottom line
Direct oral anticoagulants (DOACs) have emerged as a viable alternative to low molecular weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT). Recent evidence suggests that DOACs are effective in preventing recurrent venous thromboembolism (VTE) in cancer patients, with a comparable safety profile to LMWH. However, careful patient selection is essential due to potential bleeding risks.
What the evidence shows
Recent trials have evaluated the efficacy and safety of DOACs in the context of CAT. The SELECT-D trial (2018) demonstrated that rivaroxaban significantly reduced the risk of recurrent VTE compared to dalteparin, although with a higher incidence of clinically relevant non-major bleeding (PMID: 29231094). This trial provided early evidence supporting the use of DOACs in cancer patients, particularly those without a high risk of bleeding.
The Hokusai VTE Cancer study (2018) further confirmed the efficacy of edoxaban, showing a reduction in recurrent VTE compared to dalteparin, albeit with an increased risk of major bleeding, particularly in patients with gastrointestinal cancers (PMID: 30535375). These findings highlight the importance of individualized treatment decisions based on cancer type and bleeding risk.
A systematic review by Li et al. (2020) reinforced the potential role of DOACs in CAT management, noting their convenience and efficacy, but also emphasizing the need for vigilance regarding bleeding complications (PMID: 32045678).
Caveats and uncertainty
While DOACs offer advantages such as oral administration and fixed dosing, they are associated with an increased risk of bleeding in certain cancer populations, particularly those with gastrointestinal or genitourinary malignancies. The decision to use DOACs should be guided by a thorough assessment of bleeding risk and patient-specific factors, including renal function and potential drug interactions.
Additionally, the long-term safety of DOACs in cancer patients remains under investigation, and their use in patients with thrombocytopenia or those undergoing certain cancer treatments may require caution. Cost considerations and insurance coverage may also influence treatment decisions.
How this may change practice
The evidence supporting DOACs in CAT management may lead to their increased use as an alternative to LMWH, particularly for patients who prefer oral administration and have a lower risk of bleeding. As guidelines evolve, DOACs may become a more prominent option in the treatment algorithm for CAT, offering a balance between efficacy and convenience.
Clinicians should engage in shared decision-making with patients, discussing the potential benefits and risks of DOAC therapy. Regular monitoring and follow-up are essential to manage any adverse effects and ensure optimal treatment outcomes.